NextCell Pharma AB

Stockholm Stock Exchange NXTCL.ST

NextCell Pharma AB Shares (Diluted, Weighted) for the year ending August 31, 2024: 40,814,386

NextCell Pharma AB Shares (Diluted, Weighted) is 40,814,386 for the year ending August 31, 2024, a 18.72% change year over year. Shares (diluted, weighted) are the number of outstanding shares used to calculate earnings per share (EPS) assuming the conversion of all potentially dilutive securities.

NextCell Pharma AB Shares (Diluted, Weighted) for the year ending August 31, 2023 was 34,379,523, a 0.00% change year over year.
NextCell Pharma AB Shares (Diluted, Weighted) for the year ending August 31, 2022 was 34,379,523, a 13.05% change year over year.
NextCell Pharma AB Shares (Diluted, Weighted) for the year ending August 31, 2021 was 30,411,847, a 53.09% change year over year.
NextCell Pharma AB Shares (Diluted, Weighted) for the year ending August 31, 2020 was 19,864,756, a 60.47% change year over year.

Key data

Date	Shares (Diluted, Weighted)	Revenue	Cost of Revenue	Gross Profit

Stockholm Stock Exchange: NXTCL.ST

NextCell Pharma AB

CEO	Dr. Mathias Svahn Ph.D.
IPO Date	July 13, 2017
Location	Sweden
Headquarters	Karolinska Institutet Science Park
Employees	17
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

NextCell Pharma AB, a biopharmaceutical company, engages in the research and development of novel stem cell therapies in Sweden. The company develops ProTrans, a drug candidate comprising stem cells primarily for treating autoimmune and inflammatory diseases. It also provides Cellaviva, a stem cell bank for the family-saving of stem cells from umbilical cord blood and umbilical cord tissue. NextCell Pharma AB was incorporated in 2014 and is based in Huddinge, Sweden.

Key trends

Past 5 years